EMA

The European Medicines Agency (EMA) is the decentralised agency of the European Union responsible for the scientific evaluation, supervision + safety monitoring of medicines for human + veterinary use in the EU + EEA. Established in 1995 by Regulation (EEC) No 2309/93 (recast as Regulation (EC) No 726/2004), EMA was originally based in London and relocated to Amsterdam in March 2019 as a consequence of Brexit.

EMA itself does not grant marketing authorisations. Its scientific committees (chiefly the CHMP for human medicines + the CVMP for veterinary medicines) adopt scientific opinions on whether a medicine should be authorised, varied, suspended or withdrawn. The European Commission then issues a legally binding decision (a Commission Implementing Decision) valid throughout the EU/EEA. This two-step structure means EMA is the scientific brain + the Commission is the legal hand.

EMA's work is divided across seven scientific committees: CHMP (Committee for Medicinal Products for Human Use), CVMP (veterinary equivalent), PRAC (Pharmacovigilance Risk Assessment Committee), COMP (orphan designation), PDCO (paediatric — Paediatric Investigation Plans), CAT (advanced therapy medicinal products), HMPC (herbal medicinal products). Additional working parties + scientific advisory groups support specific therapeutic areas.

EMA works in close coordination with the EU/EEA national competent authorities (NCAs) — BfArM (Germany), AIFA (Italy), AEMPS (Spain), ANSM (France), MHRA pre-Brexit, etc. — through the Heads of Medicines Agencies (HMA) network. NCAs handle nationally authorised products, conduct GMP / GCP / GLP inspections on behalf of EMA, and host (Co-)Rapporteurs for centralised-procedure applications.

The EU operates four marketing-authorisation procedures. EMA leads one (the centralised) + coordinates two of the others through CMDh. The choice is partly mandatory (centralised for biotech / ATMP / orphan / certain disease areas) and partly elective.

The centralised procedure (CP) under Regulation (EC) No 726/2004 follows a defined 210-day scientific assessment clock with one mandatory clock-stop window for the applicant to respond to the List of Questions (LoQ) at Day 120.

1. Pre-submission — applicant submits a Letter of Intent ≥7 months pre-submission, requests appointment of a Rapporteur + Co-Rapporteur (typically NCA staff serving on CHMP), agrees the procedural calendar, and may engage Scientific Advice + Protocol Assistance.
2. Submission + validation (~14 days) — eCTD format mandatory; validation against EU Module 1 + technical / format checks. Failed validation defers Day 0.
3. Day 0 — assessment clock starts.
4. Day 80 — Rapporteur + Co-Rapporteur Assessment Reports (RAR / CAR) circulated to CHMP members.
5. Day 120 — CHMP adopts the List of Questions (LoQ); clock-stops for applicant response (typically 3-6 months allowed).
6. Clock restarts on receipt of LoQ responses.
7. Day 180 — joint assessment report; possible List of Outstanding Issues; possible oral explanation at CHMP.
8. Day 210 — CHMP scientific opinion adopted (positive, conditional, or negative).
9. Day 210 + ~67 days — European Commission decision-making process (translation into all official languages, Standing Committee consultation, Commission Implementing Decision).
10. Marketing authorisation granted — valid initially for 5 years; renewable to indefinite after first renewal subject to favourable benefit-risk balance.

Accelerated assessment (150 days instead of 210) is available under Article 14(9) of Reg 726/2004 for products of major public-health interest — particularly therapeutic innovation. Conditional marketing authorisation (Article 14-a) is available for serious + life-threatening conditions where comprehensive data is not yet available; renewed annually until conditions are met + the MA can be converted to a standard one. Authorisation under exceptional circumstances (Article 14(8)) is for cases where comprehensive data is unlikely to ever be obtainable; renewed annually permanently.

All EU marketing-authorisation applications use the eCTD format with the ICH M4 Common Technical Document structure + EU Module 1 specifics.

Once authorised, a centrally authorised medicinal product (CAP) is subject to lifecycle management through variations, periodic safety update reports (PSURs), risk management plans (RMPs), and ongoing pharmacovigilance per the EU GVP modules.

The 2010-2012 pharmacovigilance legislation (Reg (EU) 1235/2010 + Directive 2010/84/EU + Reg (EU) 1027/2012) substantially modernised the EU PV framework. The key elements:

• EudraVigilance — the EU adverse-reaction database, mandatory ICSR submission to EudraVigilance for all SUSAR + non-serious ADRs from EEA + worldwide for CP products, on ICH E2B(R3) format.
• PRAC — Pharmacovigilance Risk Assessment Committee; reviews ICSRs, signals, PSURs, RMPs, post-authorisation safety studies (PASS); issues recommendations to CHMP / CMDh.
• Pharmacovigilance System Master File (PSMF) — Article 8(ia) of Directive 2001/83/EC; the document describing the MAH's PV system, maintained at a single permanent location in the EU/EEA, accessible for inspection.
• Qualified Person Responsible for Pharmacovigilance (QPPV) — resident + operational in the EEA; legally accountable for the PV system.
• PSUR single assessment procedure — harmonised across EU for products with same active substance; outcome may be a variation requirement, an Article 31 referral, or no action.
• Article 31 / 5(3) / 20 referrals — formal procedures for EU-wide safety reviews + benefit-risk reassessments.
• Direct healthcare professional communications (DHPC) — coordinated EU-wide for urgent safety communications.
• Post-authorisation safety studies (PASS) + post-authorisation efficacy studies (PAES) — imposable obligations under Article 21a / Article 22 / Article 22a of Directive 2001/83/EC.
• Black-triangle scheme — additional monitoring symbol on SmPC + package leaflet for products subject to additional monitoring (new active substances first 5 years, conditional + exceptional MAs, certain biological products).
• Brexit-impact: UK marketing authorisations + Northern Ireland-only authorisations + the Windsor Framework arrangements require MAH coordination with both EMA + MHRA.

• Orphan designation — Reg (EC) 141/2000; for medicines treating life-threatening / chronically debilitating conditions affecting ≤5 in 10 000 in EU, with significant benefit demonstration. Benefits: protocol assistance, fee reductions, 10-year market exclusivity (12 years with paediatric).
• Paediatric — Reg (EC) 1901/2006; Paediatric Investigation Plan (PIP) required for most new MAAs + variations introducing new indications, posologies, pharmaceutical forms.
• Conditional marketing authorisation — Article 14-a of Reg 726/2004; for serious + life-threatening conditions where comprehensive data isn't yet available; renewed annually.
• Authorisation under exceptional circumstances — Article 14(8); where comprehensive data is unlikely ever to be obtainable; renewed annually permanently.
• Accelerated assessment — Article 14(9); 150-day clock instead of 210 for medicines of major public-health interest.
• PRIME (PRiority MEdicines) — early dialogue + enhanced scientific advice for medicines targeting unmet medical need; not a legal regulatory category but a scheme accelerating preparation.
• Compassionate use — Article 83 of Reg 726/2004; framework for pre-authorisation access to unauthorised medicines for patients with serious / life-threatening conditions.
• Adaptive pathways / Innovation Task Force (ITF) — exploratory tools for novel development approaches.
• Scientific Advice + Protocol Assistance — applicant-paid scientific consultation from CHMP via the Scientific Advice Working Party (SAWP); Protocol Assistance is the orphan-product equivalent.
• ATMP — Advanced Therapy Medicinal Products (gene therapy, cell therapy, tissue-engineered products) per Reg (EC) 1394/2007; mandatory CP route; CAT certifies quality + non-clinical data + provides scientific input to CHMP.

• eCTD validation failures at submission — EU Module 1 envelope / file-naming / metadata errors deferring Day 0.
• List of Questions (LoQ) major objections on Module 3 — particularly comparability data per ICH Q5E for biologics, process validation maturity, control strategy completeness.
• Nonclinical / clinical major objections — pivotal-study design challenged, extrapolation to EU population questioned, paediatric data missing or PIP non-compliance.
• Risk management plan inadequate — risk-minimisation measures insufficient for identified important risks; missing additional pharmacovigilance activities.
• PSMF gaps — PV system description outdated, QPPV change not properly notified, inspection-readiness concerns.
• Variation classification disputes — applicant submitted as Type IA / IB but EMA reclassifies to Type II, restarting clock + adding effort.
• Quality variations — change-control implemented without filing the variation; manufacturing-site change discovered at inspection.
• PSUR procedural issues — missed cycle, content gaps, signal-detection methodology weak.
• Pharmacovigilance inspection findings — ICSR late submission, follow-up information gaps, signal-management process inadequate.
• GMP inspection findings (EMA-coordinated, NCA-executed) — typical 483-equivalent issues (data integrity, validation, change control, deviation handling) per EU GMP Part I + II + the Annexes.
• Brexit-related issues — UK marketing-authorisation transfer not completed, batch-release in EU not properly arranged, MAH not established in EU/EEA.
• Article 5(3) / Article 31 referral — major safety / benefit-risk concerns triggering EU-wide reassessment, often with restriction of indications or product withdrawal.
• EudraVigilance ICSR data-quality findings — incomplete narrative, missing causality assessment, late submission.
• RMP-driven additional risk minimisation measures (aRMM) not implemented or not effective — educational materials uncirculated, controlled-distribution programme breached.
• Reliance procedures (e.g. EU-M4all / Article 58 for non-EU markets) — applicant treats EMA opinion as automatically transferable; receiving authority disagrees.

• Scientific Advice / Protocol Assistance engagement count + advice-incorporation rate before submission.
• eCTD validation pass rate (target: 100% on first attempt).
• Day 120 List of Questions response cycle time + major-objection count.
• Day 180 List of Outstanding Issues count + resolution.
• Day 210 outcome (positive / conditional / negative opinion).
• Time-from-LoI-to-Commission-Decision (calendar months) — typically 14-18 months for a standard CP application.
• Variation volume by type (IA / IB / II / Extension) per product per year.
• Variation cycle time vs target.
• PSUR on-time submission rate.
• ICSR on-time submission rate to EudraVigilance.
• Signal-detection cycle time (signal identification → validation → assessment).
• RMP additional-risk-minimisation-measure implementation + effectiveness.
• GMP / GCP / GLP / PV inspection outcomes (critical / major / minor findings).
• QP release on-time rate.

V5 Ultimate runs the GMP + Quality System + pharmacovigilance evidence layer that sits beneath every EMA-supervised marketing authorisation. Specifically:

• EU GMP + Annex 11 control framework — computerised-systems lifecycle, electronic-record + electronic-signature controls aligned with the EU equivalent of 21 CFR Part 11.
• QP release evidence — batch certification workflow with QP electronic-signature + supporting evidence (batch record, deviation log, OOS / OOT review, in-process + finished-product test results) compiled per Directive 2001/83/EC Article 51.
• Variation routing engine — change-control classifies proposed changes into Type IA / IB / II / Extension with the supporting evidence package staged per Reg (EC) 1234/2008 + Variations Guidelines.
• PSUR + RMP coordination — cycle calendar driven by the EURD list; safety + benefit-risk content prepared from the PV system + clinical-update log.
• ICSR generation + EudraVigilance submission — E2B(R3)-format ICSRs from the complaint + adverse-event intake module.
• Pharmacovigilance System Master File (PSMF) — living document with permanent EEA location, version-controlled, inspection-ready.
• GMP inspection readiness — site master file, validation master plan, deviation + CAPA log, change-control log, PQR / APQR cycle, training records all aligned with EU GMP Part I (Chapters 1-9) + Part II (ICH Q7) + relevant Annexes (Annex 1 sterile, Annex 11 computerised, Annex 15 qualification + validation, Annex 16 QP certification, Annex 21 import).
• ATMP-specific support — additional batch-disposition + traceability requirements per the ATMP regulation + EU GMP Part IV.
• Brexit / Windsor Framework dual-track — UK + EU batch-release coordination, parallel variation tracking with both EMA + MHRA where applicable.
• Centralised vs DCP / MRP routing logic — change-impact assessment routes to the correct procedural authority + tracks Reference / Concerned Member State dependencies.